RXMD - Progressive Care Inc. Subsidiary PharmCo, LLC Earns Top Performance Scores From Humana Inc.
BY GlobeNewswire
— 8:00 AM ET 08/22/2018
MIAMI , Aug. 22, 2018 (GLOBE NEWSWIRE) -- Progressive Care Inc. , a personalized healthcare services and technology company, today announced that its wholly owned subsidiary PharmCo, LLC has met all three of the performance measures evaluated by Humana Inc., a leading health and well-being company, as part of its Rx Quality Network program. As a result of PharmCo’s performance scores in the first measurement period, the company will receive the maximum payout offered by Humana as part of the program’s rewards.
Image: PharmCo Pharmacy Humana Inc. Scores
PharmCo Pharmacy has met all three of the performance measures evaluated by Humana Inc., a leading health and well-being company, as part of its Rx Quality Network program.
Provided by Humana Pharmacy Solutions, a division of Humana Inc., the Rx Quality Network focuses on the health outcomes of patient care related to medication adherence, in addition to rewarding pharmacies for adherence performance. The program aims to partner with participating pharmacies to improve member adherence in targeted drug classes, which may result in higher-quality care. The quality-based network rewards pharmacies on performance and establishes their pharmacy in-network/preferred for PDP/MAPD plans.
“We are very proud of the performance scores PharmCo Pharmacy received as part of Humana’s Rx Quality Network program. These scores are a testament to the quality of care we offer patients,” said S. Parikh Mars, Chief Executive Officer of Progressive Care Inc. ( RXMD
Loading...
Loading...
) “It is our hope that, as a result of consistently strong adherence results, physicians contracted with Humana will continue to lean on PharmCo as a trusted, high-quality provider. We believe that our success with initiatives like this one will lead to more opportunities for growth and allow us to provide even more patients with Progressive Care’s adherence packaging, proactive engagement model and pharmacological expertise.”
